UNITED THERAPEUTICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 264.3 USD | +0.03% |
|
+1.47% | +20.21% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 2.73B | Sales 2025 * | 2.94B | Capitalization | 11.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.18B | Net income 2025 * | 1.28B | EV / Sales 2024 * | 3.38 x |
| Net cash position 2024 * | 2.48B | Net cash position 2025 * | 3.95B | EV / Sales 2025 * | 2.65 x |
| P/E ratio 2024 * |
10.9
x | P/E ratio 2025 * |
10
x | Employees | 1,168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.63% |
More Fundamentals
* Assessed data
More news
Latest transcript on United Therapeutics Corporation
More recommendations
More press releases
More news
| 1 day | +0.03% | ||
| 1 week | +1.47% | ||
| Current month | +12.81% | ||
| 1 month | +13.65% | ||
| 3 months | +23.67% | ||
| 6 months | +17.31% | ||
| Current year | +20.21% |
1 week
260.41
269.81
1 month
230.39269.81
Current year
208.62269.81
1 year
204.44269.81
3 years
158.38283.09
5 years
74.31283.09
10 years
74.31283.09
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 69 | 96-06-25 | |
| President | 52 | 11-03-31 | |
James Edgemond
DFI | Director of Finance/CFO | 56 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Raymond Kurzweil
BRD | Director/Board Member | 76 | 01-12-31 |
| Chief Executive Officer | 69 | 96-06-25 | |
Tommy Thompson
BRD | Director/Board Member | 81 | 09-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.06% | 1 M€ | -2.17% | - | |
| 2.87% | 2 M€ | +9.27% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 264.3 | +0.03% | 349,600 |
| 24-05-10 | 264.3 | -0.67% | 391,702 |
| 24-05-09 | 266 | +1.90% | 474,260 |
| 24-05-08 | 261.1 | -1.93% | 581,242 |
| 24-05-07 | 266.2 | +2.19% | 686,557 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotes
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
264.3
USD
Average target price
292.7
USD
Spread / Average Target
+10.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.21% | 11.73B | |
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +46.00% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
- Stock Market
- Equities
- UTHR Stock
